Updates are available Correction dated 2024-05-16
Click to view Correction: https://doi.org/10.1038/s41590-024-01864-3
-
Authors
Gamble, Noah http://orcid.org/0000-0002-0392-452X
Bradu, Alexandra http://orcid.org/0000-0002-2237-034X
Caldwell, Jason A. http://orcid.org/0000-0002-9728-8690
McKeever, Joshua http://orcid.org/0000-0002-9750-3135
Bolonduro, Olubusayo
Ermis, Ebru
Kaiser, Caroline http://orcid.org/0000-0003-2731-407X
Kim, YeEun http://orcid.org/0000-0003-3347-183X
Parks, Benjamin http://orcid.org/0000-0002-0261-7472
Klemm, Sandy
Greenleaf, William J. http://orcid.org/0000-0003-1409-3095
Crabtree, Gerald R. http://orcid.org/0000-0001-9685-7911
Koh, Andrew S. http://orcid.org/0000-0002-4198-0143
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35-GM138150, T32-GM139782)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (T32-AI07090)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (CA-163915)
- License Information
-
More Information
Article History
Received: 27 June 2023
Accepted: 11 March 2024
First Online: 17 April 2024
Competing interests
: G.R.C. is a founder and stockholder in Foghorn Therapeutics. W.J.G. is a consultant of and equity holder in 10X Genomics, Guardant Health, Quantapore and Ultima Genomics. W.J.G. is a cofounder of Protillion Biosciences and named on patents describing ATAC–seq. The other authors declare no competing interests.
